[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"covid19-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:covid19-infection":50},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":5},"100543389","phase-1-covid-19-and-influenza-oral-vaccine-study-100543389",false,"NCT06355232","Covid-19 and Influenza Oral Vaccine Study","A Binded, Randomised, Controlled Cross-over Trial to Assess the Safety and Efficacy of Mucosal Covid-19 and Influenza Vaccines","Inclusion Criteria:\n\n* Able to provide written informed consent\n* Males or females 18 years of age or older\n* Understand and are likely to comply with planned study procedures and be available for all study visits.\n* Do not plan to have a non-study COVID-19 or influenza vaccine within the next 6 months.\n\nExclusion Criteria:\n\n* Allergy to COVID-19 or seasonal influenza vaccine or one of its components e.g. polysorbate 80.\n* Have received a COVID-19 or influenza vaccine or an experimental agent within 30 days prior to the study vaccination or expect to receive another experimental agent or a COVID-19 or influenza vaccine during the trial reporting period.\n* Any serious medical, social or mental condition which, in the opinion of the investigator, would be detrimental to the subjects or the study.",true,"ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The purpose of the current study is to assess the effectiveness of protein-based COVID-19 or influenza vaccines when given individually or together via oral\u002F sublingual mucosal route instead of intramuscular delivery. The comparator will be a seasonal influenza vaccine which will also be administered with Advax-CpG adjuvant via the oral route. This study will use a cross-over design and everyone in the study will over a space of about 4 months receive both the COVID-19 and influenza vaccines.",[27,28],"covid19 Infection","Influenza, Human",[30,31,32,33,34,35,36,37],"covid-19","influenza","pandemic","mucosal","spikogen","advax","adjuvant","vaccine","RECRUITING","2025-09-16",{"date":41,"type":42},"2025-09-17","ACTUAL",{"date":44,"type":42},"2024-05-01",{"date":46,"type":21},"2026-12-31",{"name":48,"class":49},"Vaxine Pty Ltd","INDUSTRY","COVID19 Infection"]